©The Author(s) 2022.
World J Gastrointest Pharmacol Ther. Jul 5, 2022; 13(4): 47-56
Published online Jul 5, 2022. doi: 10.4292/wjgpt.v13.i4.47
Published online Jul 5, 2022. doi: 10.4292/wjgpt.v13.i4.47
Table 1 Demography, clinical and biochemical profile of all primary hyperparathyroidism patients
| Parameters | n = 51 |
| Age (yr) | 47.80 ± 14.51 |
| Female gender | 31 (60.78%) |
| Sex (female: male) | 1.55:1 (female 31, male 20) |
| Bone pain | 28 (54.90%) |
| Fracture | 04 (7.84%) |
| Pain abdomen | 22 (43.13%) |
| Nausea and vomiting | 16 (31.37%) |
| Weight loss | 12 (23.52%) |
| Fatigue and weakness | 25 (49.01%) |
| Anorexia | 16 (31.37%) |
| Psychiatric features | 06 (11.76%) |
| Nephrolithiasis | 17 (33.33%) |
| Nephrocalcinosis | 11 (21.56%) |
| Cholelithiasis | 04 (7.84%) |
| Serum creatinine (mg/dL) | 0.80 (0.63-1.14) |
| Serum corrected calcium(mg/dL) | 12.41 ± 1.58 |
| Serum phosphorous (mg/dL) | 2.7 (2.2-3.17) |
| Serum magnesium (mg/dL) | 1.80 (1.7-2) |
| Serum albumin (g/dL) | 3.90 (3.5-4.2) |
| Serum alkaline phosphatase (IU/L) | 196 (127.5-502) |
| Serum 25-OH vitamin D (ng/mL) | 18.09 ± 9.93 |
| Plasma iPTH (pg/mL) | 328.10 (143-1111) |
- Citation: Rashmi KG, Kamalanathan S, Sahoo J, Naik D, Mohan P, Pottakkat B, Kar SS, Palui R, Roy A. Primary hyperparathyroidism presenting as acute pancreatitis: An institutional experience with review of the literature. World J Gastrointest Pharmacol Ther 2022; 13(4): 47-56
- URL: https://www.wjgnet.com/2150-5349/full/v13/i4/47.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v13.i4.47